Home >> Profile >> Yatheendradas C.k.

Yatheendradas C.k.

Yatheendradas C.k.

City: Bangalore

Joining Date: 11 Jul , 2009
Last Login: 06:09 AM - 20 Oct , 2017
IP Address of Last Login - 122.167.175.xxx
Profile Verified by Mobile.

New Thread: Home Remedies for KIDNEY DETOXIFICATION

From : Yatheendradas C.k. at 06:09 AM - Oct 20, 2017 ( )




Kidney detoxification is a long process. Juice fasting and a diet high in raw food can greatly benefit the kidneys.


Our liver and kidneys enlarge due to the added workload of protein metabolism.  If you are an individual with kidney problems, diabetes, hypoglycemia or hepatitis, a high protein diet worsens the condition.  A damaged liver or kidney does not do well when overloaded with protein digestion.  When the filtering organs are overburdened, the blood becomes more toxic and tends to aggravate other conditions.


DNA and RNA contain purines that are the primary building blocks of our genetic code.  Meat eating causes large quantities of purines to break down and form uric acid.  Uric acid causes gout and kidney stones.  The good news is that both these ailments are cured with a low-protein diet.

Fruit and vegetable juices assist in kidney detoxification.

Fruit and vegetable juices are the cleansers, energizers, builders, and regenerators of the human system.  A combination of either fresh, raw fruit or vegetable juices will supply all the enzymes, vitamins, minerals, protein and fats critical to increased vitality!  By adding live juices to one's diet as a daily routine, many have experienced a rejuvenating effect and healing of various illnesses such as cancer, leukemia, arthritis, high blood pressure, kidney disorders, skin infections, liver disorders, alcoholism and smoking.  Supplying the body with easily-absorbed nutrients, while the body is cleansing itself in the fasting state, avoids the dangers of total abstinence associated with water fasting.  Be confident that this method is both safe and beneficial.


Grapes: There are between 40 and 50 different varieties of grapes that come in a rainbow of greens, whites, reds and purples.  Grapes fill the mouth with an explosion of delicious flavors.  Grapes are an excellent source of potassium, which encourage an alkaline blood balance and also stimulate the kidneys and regulate heartbeat.  The restorative power of grapes is phenomenal, cleansing the liver and removing the uric acid from the body.  In France, many people go on a grape fast during harvest time.  Studies have shown a lower incidence of cancer in the areas of France where this grape fast is practiced yearly. 


Asparagus: Available in early spring.  It can be expensive due to the difficulty in cultivating.  Its claim to fame is the amino acid aspargagine that is destroyed by cooking.  Aspargagine is a strong diuretic, stimulating the kidneys.  Asparagus is a great blood cleanser and excellent for healthy bowel maintenance. 


Parsley: Ancient civilizations have used parsley in medications and in poultices on wounds, boils, cysts and to draw the pus out of an infected cut.  Parsley is one of the highest sources of life-giving chlorophyll, which acts like iron to oxidize the blood.  Chlorophyll will help neutralize the strong odor of garlic, and is used in chewing gum to sweeten breath.  It is a cleanser of the kidneys, liver, and urinary tract.  Parsley is effective for upset stomachs by stimulating digestive enzymes.  Excellent for the colon by encouraging the peristaltic wave in the intestines.


Spinach: Never cook spinach.  Oxalic acid is destroyed when heat transforms it into oxalic acid crystals that are harmful to the kidneys.  It also binds to iron, making it unabsorbable. 


Cranberry Juice 
A powerful healing tonic filled with quinine, which changes to hippuric acid in the liver.  Hippuric acid is able to assist in the removal of purines, uric acid, urea and toxic build-up in the prostate gland, testicles, kidneys and bladder. 


Kidney detoxification Problems:

Fasting can irritate damaged kidneys due to the amount of toxins they filter.  Try short juice fasts of 3-to-5 days before progressing to longer fasts.  To maintain the healing, you will need to permanently remove high-protein meals, refined flours, commercial oils and fats from your diet. 

Carl W. from Oshawa, ON 
(kidney and liver detoxification testimony)
Fasting with water, juice and a complete diet of natural foods gave me a new lease on life!  The disease crippling me was chronic hepatitis.  Drug abuse began at thirteen, and after years of serious addiction, I contracted hepatitis, a very painful and frustrating illness. 


As the years progressed my liver deteriorated, causing my other filtering organs (kidneys and spleen) to be overworked, thus damaging them, causing even more pain.  For sixteen years I suffered.  My liver was swollen to the size of a football.  The liver is the largest cleansing organ, and does not have room for swelling.  When it does, constant irritating pain is felt from the rib cage to the stomach.  Hepatitis is impossible to forget. 


Life was dismal and without hope.  I was a 270-lb., burned out drug addict coming off a massive intake of chemicals.  It took 20 to 30 tranquilizers a day to prevent my mind from losing its sanity. 


My emotions were out of control.  Nerves were like electrical wires on overload.  Without knowing what else to do I phoned Tom, a friend I had not seen in years.  Tom's heart was moved.  He explained that I was in serious trouble and needed help. 


After a few days of mostly sleeping, I awoke only to realize how grossly complicated my rebellious life had become.  The past 20 years flooded my conscious.  I had played the role of someone else, someone tough, ruthless, and invincible.  All that was left was an empty, barren soul.  The flood of tears wouldn't stop as I agonized over the loss of my family.  There was no one to blame I was a victim of my own demise.  I thought moving in with Tom would help the massive depression that was now my life, but nothing could stop my eyes from seeing painful reality.  Tom stayed up several nights listening to my sad story.  If all my pent up anguish hadn't found an outlet, my insides would have exploded. 


After 20 days of juice fasting the changes were remarkable.  As the pain lessened, I started to feel alive again.  I wasn't cured, but because of the  results, I continued the fast. 


After 40 days of juice fasting, there was a metamorphosis from a sickly, unstable human into someone vibrant with health and well-being.  Gradually,  my self-esteem began to build as I shed 100 pounds.  At the start, I weighed 270 lbs.  This bulk was caused by the retention of large amounts of body fluids.  Due to the drugs and the damaged liver, my body could not release these fluids.  After the 40 days my weight had dropped to 170 lbs.; whatever had caused the bloating had healed.  The swelling on my right side from my liver had disappeared completely.  My mind was clear and stable.  For the first time in years, I could live without tranquilizers!  I sincerely thought drugs had done permanent damage to my brain.  I was wrong!


If a butterfly could talk of its experience of changing from a crawling insect into a multi-colored, graceful, flying creation, it would most likely be saying the words I felt in my heart.  I was given back what drugs took away.

You have just read some excerpts from the ultimate detox program.




Warning: The reader of this article should exercise all precautionary measures while following instructions on the home remedies from this article. Avoid using any of these products if you are allergic to it. The responsibility lies with the reader and not with the site or the writer.
This information is solely for informational purposes. IT IS NOT INTENDED TO PROVIDE MEDICAL ADVICE and should not be treated as a substitute for the medical advice of your own doctor.

Source : email

New Thread: Diagnosing cancer

From : Yatheendradas C.k. at 06:04 AM - Oct 20, 2017 ( )

Diagnosing cancer

Difference Engine: Blissful ignorance
Click here to join World Malayali Club or visit http://groups.*.com/group/worldmalayaliclub/
MEN in America, Europe and other developed regions of the world have a 16% chance of being diagnosed with prostate cancer at some point during their lives—and yet they have only a 3% chance of dying from the disease. Despite the statistics, an industry has grown up around treating prostate cancer which, in most cases, would be best left well alone. The problem is finding the few instances where the cancer is aggressive enough to spread. Unfortunately, lacking better diagnostics, 48 men have to be needlessly treated—at considerable discomfort and possible change in lifestyle for the worse—so that one man’s life may be spared.

Three out of four men in America aged 50 or older have had a PSA test, often unbeknown to themselves during a routine check-up. The test measures the amount of prostate-specific antigen floating around in the blood. PSA is a protein made in the prostate gland to help sperm do its job. The test, which  has nothing directly to do with a man’s reproductive capacity, is carried out solely to screen for prostate cancer. 

So, what is wrong with that? For a start, while elevated levels of PSA in the blood can indicate the presence of cancer cells in the prostate, higher levels than normal can also be caused by an enlarged prostate (common in older men), infection, inflammation, irritation, head-ache pills like ibuprofen, and whether the person concerned recently had sex. Even a doctor’s digital rectal examination (“thumb up the bum”) can raise a patient’s PSA level. 

The widely used PSA test has been criticised for giving too many false-positive results, which, in turn, lead to over-treatment of cancers that might never have caused harm. Among men with PSA levels in the warning zone (between four and ten nanograms of PSA per millilitre of blood), biopsies show that over two-thirds of them had no trace of prostate cancer. Meanwhile, one in six men with PSAs in the normal zone (below 4ng/mL) were subsequently found to have been harbouring cancer cells in their prostate glands.

Usually a family doctor will refer a patient to a urologist if his PSA level is above 4ng/mL—or if the level rises by more than 0.35ng/mL over the course of a year. Because of the vagaries of the PSA blood test, many urologists confronted with borderline cases have started using a biomarker in the urine that focuses on a gene called PCA3. Comparing the activity level of the PCA3 gene with that of the PSA gene can be twice as accurate as relying on a PSA test alone. Based on such findings, the urologist may recommend a biopsy.

But that has problems, too. Tissue cores are taken from various parts of the prostate using an instrument with a dozen hollow needles that is inserted via the rectum. The sampling covers only a minuscule part of the prostate, making it easy to miss regions where cancerous cells may lurk. The procedure is not painless, can cause infection, fever, bleeding, problems with urination, and other conditions requiring hospitalisation.
In the laboratory, a pathologist slices the cylindrical biopsy samples taken from the patient’s prostate and examines them under a microscope. A grade is assigned, first, to the most common tumour pattern and, second, to the next most common pattern. The two grades, each with ranges 1 to 5, are added together to give what is called a Gleason score ranging from  2 to 10. For a Gleason score of 7, the combination 4+3 denotes a more aggressive cancer than 3+4. 

With a Gleason score of 6 or less, the urologist may advise active surveillance rather than surgery or radiation. “Watchful waiting” involves tracking the PSA level every three months or so and having an annual biopsy. That may be the best advice the patient will ever receive. But it does require that the person is content to live with the knowledge that he has cancer and has chosen not to have it treated. Most men find that daunting—and opt for treatment, even though medically it may not be warranted.

Even in cases where a biopsy proves positive, the majority of cancer cells found are likely to be localised and to grow so slowly as never to cause even the symptoms of prostate cancer, let alone death. The condition has been likened to a handful of tortoises crawling around the bottom of a well. In the vast majority of instances, they remain trapped at the bottom. But, once in a while, a tortoise manages to crawl up the side and escape into the surroundings. 

In the majority of cases, men who do nothing about cancer cells found in their prostates will most likely die in old age of something else—heart attack, stroke, lung cancer, pneumonia or whatever—long before they would have succumbed to prostate cancer. In other words, they will die with the disease, not from it. The same goes for the vast majority of men who live in blissful ignorance, having never had a PSA test. Autopsies show that three out of four men who reached the age of 85 had prostate cancer but died of other causes.
Yet, the urgency to treat any detected cancer—whether aggressive or not—can be immense. The pressure to do so can come as much from the patient himself (“Get that thing out of me!”) as from a medical professional (“To be on the safe side, we advise surgery or radiation.”). Such screening can cause serious stress and anxiety. Researchers at Harvard and Brigham & Women’s Hospital in Boston have found that just being diagnosed with prostate cancer doubles the risk of dying from heart attack or suicide.

If over-detection resulting from PSA screening and biopsies has its risks, over-treatment involves even bigger ones. None of the treatments—and there are half a dozen or so different ones to chose from—is benign. 

Among men who opt to have their prostates removed—often to treat cancers that would never have harmed them—0.5% die within a month due to complications from the surgery. Up to 7% have serious problems but survive. And between 20% and 30% of those treated with surgery or radiation finish up with erectile dysfunction, urinary incontinence and other disabilities. Of those who use chemotherapy to suppress the hormones that feed cancerous cells in the prostate, 40% become impotent.

If truth be told, the PSA test can cause more grief than relief. There is no evidence that the test provides any advantages, even to men who turn out to have the fast-growing version of the disease. The first sign of the invasive form of prostate cancer occurs too late for it to be treated successfully. No amount of screening will prevent those destined to develop the deadly, untreatable form of the disease from doing so. In the final analysis, PSA screening has allowed more prostate cancers to be detected, but it has not lowered the death rate from the disease. 

Even the scientist who discovered PSA over 40 years ago has argued vociferously for routine testing of prostate-specific antigen levels to be abandoned. Richard Ablin, professor of immunobiology and pathology at the University of Arizona, has called the test based on his work “a public health disaster” that is little better than the toss of a coin. So why is it still used? “Because drug companies continue peddling the tests and advocacy groups [encourage] men to get screened,” Dr Ablin wrote in the New York Times

Two years ago, the United States Preventive Services Task Force, an independent panel of medical experts empowered to evaluate cancer testing, recommended against PSA screening for men over 75 years of age. Being older and frailer, such men were viewed as unlikely to benefit from having surgery, radiation and other treatments that were unlikely to prolong their lives, but could well cause incontinence and impotence. At the time, the panel made no change in its recommendation for younger men.

Having reviewed the findings of leading studies in Europe and America, the Task Force has now downgraded its previous recommendation on prostate-cancer screening for younger men. In an announcement on October 7th, the panel noted that for men 50 to 69 years old the reduction in death caused by prostate cancer ten years after screening “is small to none”. In other words, the PSA test does not save lives, and is not needed by healthy men showing no symptoms of the disease. The risks it causes outweigh any benefits it may bestow. 

But even Dr Ablin admits PSA testing has a place. “After treatment for prostate cancer, for instance, a rapidly rising [PSA] score indicates a return of the disease,” he wrote in his Op-Ed piece last year. And men with a family history of prostate cancer should probably get a regular PSA test. At present, PCA3 screening looks a better bet, but it could turn out eventually to have similar drawbacks as PSA.

The real problem with prostate-cancer screening—whatever the test employed—is the over-treatment that ensues. If that could be eliminated, even the PSA test might do more good than harm. Ultimately, what is needed, of course, is a way of identifying the odd tortoise that escapes from the well, while ignoring all the other critters that will never do any harm. That is something science has yet to deliver.
Source : email

New Thread: Wealth creating opportunity! Metal sector to outperform

From : Yatheendradas C.k. at 05:57 AM - Oct 20, 2017 ( )

Oct 19, 2017 08:12 PM IST | Source: CNBC-TV18  Moneycontrol.com

Wealth creating opportunity! Metal sector to outperform, see 30-40% upside in 1 year: Atul Suri

Suri is very bullish on markets for the next 3-4 years. He sees tremendous opportunity in the metals sector. The sector rose 44 percent so far in the Samvat 2073.

The Nifty50 rose 18 percent so far in the Samvat 2073 but there is plenty of upsides left in the market, says Atul Suri, Chief Investment Officer at Marathon Trends PMS, who sees the index touching 11400 by Samvat 2075.

Although, he sees near-term pain if Nifty Bank underperforms which could lead to some consolidation in the market. The crucial support for the index stands at 9700 and a breach of which could take Nifty towards 9200 levels.

But, Suri is very bullish on markets for the next 3-4 years. He sees tremendous opportunity in the metals sector. The sector rose 44 percent so far in the Samvat 2073.

“If we look at the underlying commodities charts such as copper or zinc they are outstanding. The chart patterns developing on these charts suggest bullish bias because most of them are breaking out,” said Suri.


“Our own metal index saw double bottom formation. I think going forward we could see 30-40% move in the next one year in metals. Fortunately, numbers of players in the index are few and there is under ownership,” he said.

He further added that none of the analysts talk about metals. "How many mutual funds have their top five holding in this sector? Hardly any," he said, adding that hence, going ahead, metals are likely to continue to enjoy leadership status.

Below are the excerpts of the interview.

Latha: It has been a great year Samvat 2073. On a broad brush how does Samvat 2074 look, the next 12 months?

Suri: I have a call of 17000 on Nifty which is about a 70 percent move for the next four years but all four years can't be the same. Next year, people are very buoyant and bullish but we could have a bit of a measured index move, I would think about as 12-14 percent kind of index target and that is still not very bad.

My only issue is that, right now we are almost in a slumber bird mode in terms of volatility. The global VIX, the US VIX is at a 20 year low, so essentially markets are just enjoying this slumber kind of phase. My fear is that you will get back into moments of volatility, that I think is going to be the pain point, though I do think that we will have about 12-14 percent kind of index year which sets a target of around 11400 or thereabouts on the Nifty. It will be more stock specific rather than pure sector driven thing. There are one or two sectoral bets which I feel bullish about but it is going to be more stock specific.

Post Diwali last year, barring two months of demonetisation, after that we have had 10 months which were like cruise control on a highway in US, it has been so smooth. I feel that we will see a little more volatility, we will see a little more stock specific sort of movements. It will be good but I think the last 10 months were bit of a dream.

Anuj: The sector that stood out was commodities and resources, you could include metals, Reliance, do you see this run continuing?

Suri: If you ask me the sector that will outperform, it is metals. My reason are that if you look at the underlying global commodity charts, copper, zinc, aluminium, you will find that they are outstanding charts. This is reflected not just in charts but even in global metal companies, mining companies, you will see that kind of chart patterns that have developed. All have had huge inverted head and shoulder patterns and they are just kind of breaking out.

A similar pattern is seen if you look at our own metal index, we have had a kind of a double bottom formation. So, we could see a 30-40 percent kind of move in the next one year in metals. Fortunately the number of players are few and more so there is under ownership. It has been the best performing sector but nobody talks of metals, all are talking about financials. How many mutual fund or PMS portfolios top 5 holdings are metals? I think there will be hardly any. So, the best performing sector and nobody talks about it, nobody owns and you have a global commodity rally, I feel that going ahead for the next 12 months or so metals could continue to be in leadership status.

New Thread: Thoughts for the Day October 20th, 2017

From : Yatheendradas C.k. at 05:53 AM - Oct 20, 2017 ( )

20th October, 2017  
Image result for quotes for the day

New Thread: 30 years since Dow’s Black Monday: The lethal cocktail

From : Yatheendradas C.k. at 09:53 PM - Oct 19, 2017 ( )

Oct 19, 2017 11:55 AM IST | Source: Moneycontrol.com

30 years since Dow’s Black Monday: The lethal cocktail of events that caused the crash

On Monday, October 19, 1987, the Dow Jones Industrial Average crashed 508 points or nearly 23 percent to close at 1739. The collapse ended the five year bull run in US equities that had begun in 1982.

By Moneycontrol News

It is 30 years since the biggest single-day stock market collapse in the US, the reverberations of which sent share prices in major global markets tumbling.

On Monday, October 19, 1987, the Dow Jones Industrial Average crashed 508 points or nearly 23 percent to close at 1739. The collapse ended the five year bull run in US equities that had begun in 1982.

Much of the blame for the panic selling on that day was heaped on program trading, a strategy in which computers execute trades when certain price limits are breached


Over the years, it has become clear that the correction was caused by a combination of factors. And while program trading may have aggravated the meltdown in share prices on that day, it was certainly not the trigger for the crash. The build-up to the fateful Monday had already begun the week before, when the Dow fell 10 percent in three trading sessions, the steepest 3-day drop in almost five decades.

Till then, 1987 had been a strong year for the US stock market because of a booming economy, and strong corporate earnings growth. And then the wheels slowly began to come off the bull market.

Here is a look at the chain of events that eventually culminated in the unprecedented sell off in the US stock market.

# Strong economic and credit growth raised concerns of inflation and overheating. The Federal Reserve responded by raising short term interest rates to temper inflation. Rising interest rates hurt stock market sentiment in two ways. One, corporate profit margins shrank because of higher interest costs. Two, investors shifted some of their money from equity to debt, as they now got better rate of return at a lower risk

# Because of the 5-year long bull run, share prices were rising faster than earnings, and many commentators felt the stock market had become overvalued.

# Program trading strategies were becoming popular. Algorithms would automatically start selling stocks and index futures when certain pre-decided limits were breached.

# On October 14, a government committee proposed scrapping of tax benefits related to financing of mergers and acquisition (M&A) activity. Takeover deals--mostly hostile--financed by debt, were a rage in the US during the 80s. The proposal triggered a sell-off in many stocks thought to be potential take-over targets

# On the same day, the Commerce Department announced the trade deficit for August, which was above analysts’ estimates. This weakened the dollar, raising concerns that Fed would raise interest rates further to support the currency.

# Selling in shares accelerated on Friday (October 16), dragging down the Dow by 4 percent. Many traders sold whatever stocks they could to meet margin calls. This is believed to have reduced liquidity in the system, leaving the market vulnerable if the selling pressure continued.

# As selling pressure continued on Monday, many mutual funds were flooded with redemption requests. This triggered off a vicious cycle, as every wave of selling pushed prices lower, in turn prompting more investors to sell in panic. At some point, a steep decline in share prices triggered selling by computer programs as loss limits were breached. It is widely believed that program selling was the final nail in the coffin for the market which was already hemorrhaging. A Federal Reserve discussion paper later said “this strategy (program trading) was not entirely to blame”, and that many other institutions were heavy sellers on that day.

The following day, before the market opened for trading, the US Federal Reserve put out a statement saying it was ready “to serve as a source of liquidity to support the economic and financial system.”

Later in the day, the market stabilized as companies announced stock buyback programs to arrest the free fall in the prices of their stocks.

Over the next few days, the Fed conducted open market operations, lowered interest rates to provide liquidity to the banking system and eased the rules for lending of securities. In addition, the Fed prodded market participants, in particular banks lending to brokers and dealers, to be flexible with their customers.

All these steps helped limit the fall out of Black Monday on the US economy.

Following Black Monday, stock exchanges introduced ‘circuit breakers’ which allows exchanges to temporarily halt trading when there are steep moves down or up.


From : Yatheendradas C.k. at 09:40 AM - Oct 19, 2017 ( )

Worry that rising consumer prices will threaten
the RBI's inflaon target of 4% led the majority of
the monetary policy commiee to vote to keep
rates steady, according to minutes issued on
today. Commiee members also said at their Oct.
4 meeng they expected that a slowdown in
economic growth to its lowest in more than 3
years in the April‐June quarter could prove
transitory, and it was prudent to wait for more evidence.
‐Economic Times

Kotak Mahindra Bank today said its credit and
debit card holders will be able to tap and pay
using smartphones at merchant establishments.
The Bank has end up with Samsung, under which
its cardholders will be able to tap and pay using
smartphones having the Samsung Pay acceptance
machines, the bank statement said.
‐Economic Times

SBI has raonalised 1,000 branches in the
April‐Sep 2017 period, post acquision
of 5 associate banks and the Bharatiya
Mahila Bank, said Prashant Kumar, Deputy Managing Director,
SBI. “After the merger we had almost 24,000
branches. So far, 1,000 branches have been
raonalised. This (raonalisaon) we were
planning to do by Dec‐end but we could complete
that by Sep‐end. So, the entire branch raonalisaon part is over.”
‐Business Line

The IRDAI has directed insurers to conduct
security audit of their Informaon
and Communicaon Technology infrastructure. The
insurers should take `immediate steps’ for
conducng the audit of their systems including
Vulnerability Assessment and Penetraon
Tests (VAPT) through Cert‐in empanelled Auditors,
idenfy the gaps and ensure that audit findings
are recfied swiftly, ’’ it said in a communicaon.
‐Business Line

The Maharashtra government has released a sum
of Rs 4,000 crore under the first phase of the over
Rs 34,000 crore farm loan waiver scheme, Chief
Minister Devendra Fadnavis announced today
‐Economic Times

USD/INR 65.04
SENSEX 32584.35(‐24.81)
NIFTY50 10210.85(‐23.60)

New Thread: Dow touches 23,000 for the first time, closes at record

From : Yatheendradas C.k. at 08:40 AM - Oct 19, 2017 ( )

Oct 18, 2017 07:47 AM IST | Source: CNBC : Moneycontrol.com

Dow touches 23,000 for the first time, closes at record

"Those big, round numbers are getting easier to reach on the Dow on a percentage basis," said Art Hogan, chief market strategist at Wunderlich Securities. "That's great because every time we get a milestone like that, it seems like Mainstream America pays more attention to financial markets."

The Dow Jones industrial average rose on Tuesday, and broke above 23,000 for the first time on an intraday basis.

The index faded and closed three points shy of 23,000 as bank shares rolled over.

The Dow first crossed 22,000 for the first time just 76 days ago.

"Those big, round numbers are getting easier to reach on the Dow on a percentage basis," said Art Hogan, chief market strategist at Wunderlich Securities. "That's great because every time we get a milestone like that, it seems like Mainstream America pays more attention to financial markets."


Boeing and Caterpillar were the biggest points contributors on the Dow since Aug. 2, when the index first broke above 22,000. They added 142 points and 121 points, respectively. The two stocks have had a stellar year, rising 65.9 percent and 41.2 percent, respectively.

Home Depot and Goldman Sachs, meanwhile, contributed 97 points and 87 points to the Dow's latest 1,000-point run.

"We've had a very strong rally and we're now digesting it," said Marc Chaikin, CEO of Chaikin Analytics. "In general, I think we're going to finish the year on a very strong note."

On Tuesday, the Dow closed 40.41 points higher at 22,997.44, buoyed by shares of UnitedHealth and Johnson & Johnson. The index also posted intraday and closing records.

"I think the question here at 23,000 is: Is this a breakout or a fake-out?" said Jeff Saut, chief investment strategist at Raymond James. "I think this is a fake-out."

"Very short-term, I think we're trying to form a trading top," Saut said.

UnitedHealth reported a stronger-than-expected quarterly profit and raised its full-year adjusted earnings forecast, helped by growth across all its businesses. Shares of the largest U.S. health insurer rose 5.5 percent to hit an all-time high.

Johnson & Johnson also reported better-than-expected quarterly results, driven by its pharmaceutical business and its recent acquisition of Swiss biotech Actelion and other businesses. The company's stock rose more than 3.4 percent and hit an all-time high.

The S&P 500 rose 0.1 percent to 2,559.36, clinching intraday and closing all-time highs.

Shares of Morgan Stanley hit levels not seen since May 2008. The company's wealth management business posted strong quarterly results.

Goldman Sachs' stock slipped 2.6 percent; it briefly traded higher after its third-quarter earnings and revenue beat Wall Street expectations. Fixed income trading revenue totaled $1.45 billion, a 26 percent year-over-year drop, but was enough to top a StreetAccount estimate of $1.38 billion.

JPMorgan touched an all-time high earlier in the day before it also rolled over.

The Nasdaq composite 0.01 percent to 6,623.66 after shares of streaming giant Netflix pulled back 1.6 percent. Netflix posted better-than-expected earnings and revenue, boosted by stronger-than-expected subscriber growth. The stock hit a record high before retreating.

This earnings season is off to a good start. As of Tuesday morning, 82 percent of the companies that had reported topped Wall Street earnings estimates, while 76 percent had surpassed revenue estimates, according to Thomson Reuters I/B/E/S.

"We've had some good earnings reports and third-quarter estimates continue to go higher," said Mike Baele, managing director at U.S. Bank Private Client Reserve. "I think we're poised to have another good earnings season."

Equities reached record highs on Monday as the three major indexes continue their steady grind higher.

Hopes of U.S. tax reform have received a boost lately after the House passed a $4.1 trillion budget. The Senate is expected to vote on a budget bill later this week.

"The market has done a lot already," said Crit Thomas, global market strategist at Touchstone Investments. "I feel the market is responding to the GOP's acceptance of deficit-widening in order to get their tax cuts."

New Thread: Eye Health: 4 Natural Ways To Maintain Good Vision

From : Yatheendradas C.k. at 07:02 AM - Oct 19, 2017 ( )

Eye Health: 4 Natural Ways To Maintain Good Vision

Maintain good vision and reduce your risk of glaucoma by following these natural ways that promote good eye health throughout life.

Whether you are near-sighted or far-sighted, or have 20/20 vision, you are at risk for glaucoma. The eye disease is second leading cause of blindness,†reports the World Health Organization†(WHO), and affects over three million Americans from newborn infants to senior citizens.
The Glaucoma Research Foundation (GRF) says that half of those with glaucoma, specifically†open-angle glaucoma†(OAG), is unaware they even have the disease. OAG, the most common form of the ocular disorder, has no symptoms early in the disease process. Over time, optic nerve fibers begin to deteriorate and people with late-stage OAG will develop pain or severe visual changes,†says the University of Maryland Medical Center†(UMM). The nature of glaucoma and the severity of the disease is often misunderstood, but deserves more attention as the condition becomes more common among Americans in the U.S.

How Glaucoma Affects Your Vision

Damage to the optic nerve results from an abnormal increas in eye pressure,†high intraocular pressure†(IOP), a condition also known as ocular hypertension. High IOP occurs when the clear fluid usually located behind the iris, known as the aqueous, moves into to the area behind the iris and cornea,†says Mayo Clinic. Also, high eye pressure can result from below average aqueous drainage, as the fluid normally drains and replenishes. While a high IOP can be a significant risk factor to determine if you have glaucoma, patients with normal IOP levels are also prone to the chronic condition.
Ways To Reduce Risk of Glaucoma
There is no cure for glaucoma; treatment usually slows the progression of the disease. To reduce high eye pressure, practice a healthy lifestyle with these natural ways that help you maintain good vision.

Prevent Diabetes: Lower Your Blood Sugar Levels

Increase Your Lutein And Zeaxanthin Intake With Dark Leafy Vegetables
The increase daily intake of these two nutrients that are commonly found in dark green leafy vegetables can significantly improve your eye health. Lutein and Zeaxanthin are carotenoids that are antioxidants for your eyes,†says the American Optometric Association†(AOP). There is no recommended daily intake for these two nutrients but the AOP suggests that 10 miligrams a day of lutein and two mg/day of zeaxanthin are best to maximize health benefits of these two antioxidant nutrients.

Increase Your Bilberry Intake

Billberry √¢‚Ǩ‚Äù part of the blueberry family with roots in Northern Europe containsanthocyanins†√¢‚Ǩ‚Äù contains pigments that are rich in antioxidants. The anthocyanins found in bilberries has been linked to boost eye health. According to†UMM, the fruit has provided protective properties in combating macular degeneration, glaucoma, and cataracts.

Increase Your Workout

Regular exercise, like reducing overall hypertension, can also lower IOP levels. Exercises such as walking or jogging a minimum of three times a week is recommended by the GRF as part of a moderate exercise routine to promote good vision. As long as you continue to exercise, there will be plenty of eye health benefits to reap.

New Thread: BSNL Diwali offer: Save your computer from viruses etc

From : Yatheendradas C.k. at 05:54 AM - Oct 19, 2017 ( )

BSNL Diwali offer: Save your computer from viruses, hackers at just Re 1; here’s how

BSNL's Xgenplus Security Features is available at just Re 1 per day. Here's what it is.

By: FE Online | Published: October 18, 2017 4:33 PM

On the occasion of Diwali, state-run telecom firm BSNL announced a new anti-virus, anti-spamming, and anti-hacking plan for its subscribers. The secured email services called ‘Xgenplus Security Features’ is available at just Re 1 per day. The telecom operator had started its corporate e-mail service in partnership with a Jaipur-based company called Data Infosys. BSNL, in a statement, had said that the offer is for “users’ e-mail services to ensure privacy and security of their data”. Today, from its official Twitter handle, BSNL posted an advertisement which says: “Say no to Virus, Hacking, Spamming. Pledge to be safe with Xgenplus Security Features @ Re 1 per day.”


In the new BSNL offer, users will be able to avail the service linked to their websites for a yearly fee of Rs 365 per e-mail ID with 1GB storage and Rs 999 per e-mail ID with 10-gigabyte storage. Data Infosys CEO Ajay Data had said, “The payment will have to be made once in a year. The effective price of the service starts for Re 1 per day with 1 GB storage. For usage beyond 10 GB, customers can buy extra 5 GB storage for an annual payment of Rs 500.” In the BSNL plan, enterprise e-mail accounts will come with security tools and dual authentication that will make them hacker-free e-mail accounts, the company said.

BSNL had highlighted ‘privacy’ as key to its e-mail service. BSNL’s email service offers secure emails which are not scanned like usual email host players. BSNL Director for Enterprise Business NK Mehta informed, “E-mail solution does not allow anyone including e-mail administrator to monitor/look into an e-mail account. Entire e-mail solution is hosted on BSNL Network, giving lawful rights and access speed at its best.”

BSNL’s e-mail service also has a mobile app for access to cellphones. It can be hosted on domains owned by the customers, and the service is meant for both corporate and personal subscribers. The new email platform supports sending of group emails, scheduling emails, merging multiple email accounts, folder sharing, delivery receipts, and access through a mobile application.

New Thread: Thoughts for the Day August 19th, 2017

From : Yatheendradas C.k. at 05:47 AM - Oct 19, 2017 ( )

19th October, 2017  

Image result for quotes for the day

New Thread: What Is Ashwagandha, and Why Is It in Your Food?

From : Yatheendradas C.k. at 09:37 PM - Oct 18, 2017 ( )

What Is Ashwagandha, and Why Is It in Your Food?

You may have noticed some new words on your health foods lately, from reishi to maca and everything in between. What are these things? How do you even pronounce them? Today we're going to dive into a superfood trend that's actually not so new (in fact, it's pretty ancient): ashwagandha. You may have noticed it on your kombucha labels or on supplement shelves at the grocery store, but what is it?

What Is Ashwagandha?

Ashwagandha is a superherb and adaptogen used in Ayurvedic healing and traditional Chinese medicine. The shrub from which it grows - also known as withania somnifera, Indian ginseng, and poison gooseberry (yikes) - is part of the nightshade family (like tomatoes), and the fruit it yields looks like a red berry. It originally was grown in northern Africa, India, and parts of the Middle East, though now it also grows in temperate and mild climates in the United States.

The roots of the ashwagandha plant are dried and ground into the powdery herb. Ashwagandha extract is also derived from this plant for healing purposes.

What Does It Do?

In Sanskrit, ashwagandha actually means "smell of a horse," (yum) which has less to do with the actual smell of the herb and more about its revitalizing properties. This herb was known to give the "strength of a stallion" by Ayurvedic practitioners in India.

As for possible healing properties within natural medicine and holistic treatment, here are some benefits ashwagandha is used for (and some have been scientifically studied within the past 10 years!):

  • Stress relief and cortisol reduction
  • Fighting fatigue and boosting energy
  • Reducing anxiety and depression
  • Improving mood
  • Heightening focus and mental clarity
  • Increasing stamina
  • Boosting the immune system

What Do You Do With It?

You eat it! Ashwagandha is offered in capsules and powder form most often, but you can also find it in fancy drinks, teas and tinctures, and in certain types of ghee and honey. If you go the capsule route, you can add it into your vitamin or natural supplement routine. Thinking about trying the powders? Make a superfood cocoa or mix it into your smoothieor juice - maybe even a spicy veggie dish! Just want to give it a try before committing? Check out Suja's ginger kombucha with ashwagandha or Rebbl's ashwagandha chai (both of which can be found at Target).


Ashwagandha is all natural and has been used for centuries, but as with everything, be mindful about your use if you start consuming it in larger quantities. Whether you add it to your food as a supplement or start buying products infused with this superherb, it's always a good idea to consult your doctor and/or dietitian before making big changes to your supplement routine.

From: yatheendradas c.k. at 09:43 PM - Oct 18, 2017( )

12 Proven Health Benefits of Ashwagandha

Ashwagandha is an incredibly healthy medicinal herb.

It is classified as an "adaptogen," meaning that it can help your body manage stress.

Aswhagandha also provides all sorts of other benefits for your body and brain.

For example, it can lower blood sugar levels, reduce cortisol, boost brain function and help fight symptoms of anxiety and depression.

Here are 12 benefits of ashwagandha that are supported by science.

1. It's an Ancient Medicinal Herb

Ashwagandha is one of the most important herbs in Ayurveda, a form of alternative medicine based on Indian principles of natural healing.

It has been used for over 3,000 years to relieve stress, increase energy levels and improve concentration (1).

"Ashwagandha" is Sanskrit for "smell of the horse," which refers to both its unique smell and ability to increase strength.

Its botanical name is Withania somnifera, and it is also known by several other names, including Indian ginseng and winter cherry.

This is what the ashwagandha plant looks like: The ashwagandha plant is a small shrub with yellow flowers that's native to India and North Africa. Extracts or powder from the plant's root or leaves are used to treat a variety of conditions.

Many of its health benefits are attributed to the high concentration of withanolides, which have been shown to fight inflammation and tumor growth (1).

BOTTOM LINE:Ashwagandha is a prominent herb in Indian Ayurvedic medicine and has become a popular supplement due to its health benefits.

2. It Can Reduce Blood Sugar Levels

In several studies, ashwagandha has been shown to lower blood sugar levels.

A test-tube study found that it increased insulin secretion and improved insulin sensitivity in muscle cells (2).

Several human studies have confirmed its ability to reduce blood sugar levels in both healthy people and those with diabetes (3456).

In one study in people with schizophrenia, those treated with ashwagandha for 4 weeks had an average reduction in fasting blood sugar levels of 13.5 mg/dL, compared to a 4.5 mg/dL reduction in those who received a placebo (5).

What's more, in a small study of 6 people with type 2 diabetes, supplementing with ashwagandha for 30 days lowered fasting blood sugar levels as effectively as an oral diabetes medication (6).

BOTTOM LINE:Ashwagandha may reduce blood sugar levels through its effects on insulin secretion and sensitivity.

3. It Has Anti-Cancer Properties

Animal and test-tube studies have found that ashwagandha helps induce the apoptosis or "programmed cell death" of cancer cells (7).

It also impedes the growth of new cancer cells in several ways (7).

One of these ways is believed to be the generation of reactive oxygen species (ROS), which are toxic to cancer cells but not normal cells. Another mechanism causes cancer cells to become less resistant to apoptosis (8).

Animal studies suggest that it may be beneficial for treating several types of cancer, including breast, lung, colon, brain and ovarian cancer (910111213).

In one study, mice with ovarian tumors treated with ashwagandha alone or in combination with an anti-cancer drug had a 70–80% reduction in tumor growth. The treatment also prevented metastasis, the spread of cancer to other organs (13).

Although there are no studies to confirm these results in humans yet, the research to date is encouraging.

BOTTOM LINE:Animal and test-tube studies have shown that it promotes the death of tumor cells and may be effective against several types of cancer.

4. It Can Reduce Cortisol Levels

Cortisol is known as a "stress hormone" because your adrenal glands release it in response to stress and when your blood sugar levels get too low.

Unfortunately, in some cases, cortisol levels may become chronically elevated, which can lead to high blood sugar levels and increased fat storage in the abdomen.

Studies have shown that ashwagandha may help reduce cortisol levels (31415).

In a controlled study of chronically stressed adults, the group that supplemented with ashwagandha had significantly greater reductions in cortisol than the control group. The group taking the highest dose had a 30% reduction, on average (3).

BOTTOM LINE:Ashwagandha supplements may help lower cortisol levels in chronically stressed individuals.

5. It May Help Reduce Stress and Anxiety

Ashwagandha is perhaps best known for its ability to reduce stress.

Researchers who looked at its effects on rat brains reported that it blocked the stress pathway by regulating chemical signaling in the nervous system (16).

Several controlled human studies have shown that it can effectively reduce symptoms in people with stress and anxiety disorders (141718).

In a 60-day study of 64 people with chronic stress, those in the ashwagandha group reported a 69% average reduction in anxiety and insomnia, compared to 11% in the placebo group (14).

In another study lasting 6 weeks, 88% of people who took ashwagandha reported a reduction in anxiety, compared to 50% who took a placebo (18).

BOTTOM LINE:Ashwagandha has been shown to reduce stress and anxiety in both animal and human studies.

6. It May Reduce Symptoms of Depression

Although it hasn't been studied much, a couple of studies suggest ashwagandha may help alleviate depression (1418).

In a controlled 60-day study in stressed adults, those who took 600 mg per day reported a 79% reduction in severe depression. At the same time, the placebo group reported a 10% increase (14).

BOTTOM LINE:The limited research available suggests that ashwagandha may help reduce severe depression.

7. It Can Boost Testosterone and Increase Fertility in Men

Ashwagandha supplements may have powerful effects on male hormone levels and reproductive health (15192021).

In a study of 75 infertile men, the group treated with ashwagandha had an increase in sperm count and motility.

What's more, the treatment led to a significant increase in testosterone levels (21).

The researchers also reported that the group who took the herb experienced increased antioxidant levels in the blood.

In another study, men who received ashwagandha for stress experienced higher antioxidant levels and better sperm quality. After 3 months of treatment, 14% of the men's partners had become pregnant (15).

BOTTOM LINE:Ashwagandha helps increase testosterone levels and significantly boosts sperm quality and fertility in men.

8. Ashwagandha May Increase Muscle Mass and Strength

Research has shown that ashwagandha may improve body composition and increase strength (42022).

One study's purpose was to determine a safe and effective dosage for ashwagandha. Healthy men who took 750–1250 mg per day had gained muscle mass and lost fat after 30 days (4).

In another study, the ashwagandha group had significantly greater gains in muscle strength and size. It also had more than double the reduction in body fat percentage compared to the placebo group (20).

BOTTOM LINE:The herb has also been shown to increase muscle mass, reduce body fat and increase strength in men.

9. It May Reduce Inflammation

Several animal studies have shown that ashwagandha helps decrease inflammation (232425).

Studies in humans have found that it increases the activity of natural killer cells, which are immune cells that fight infection and help you stay healthy (2627).

It has also been shown to decrease markers of inflammation, such as C-reactive protein (CRP). This marker is linked to an increased risk of heart disease.

In a controlled study, the group who took 250 mg of ashwagandha daily had a 36% average decrease in CRP, compared to a 6% decrease in the placebo group (3).

BOTTOM LINE:Ashwagandha has been shown to increase natural killer cell activity and decrease markers of inflammation.

10. It May Lower Cholesterol and Triglycerides

In addition to its anti-inflammatory effects, ashwagandha may help improve heart health by reducing cholesterol and triglyceride levels.

Animal studies have found that it significantly decreases these blood fats.

One study in rats found that it lowered total cholesterol by as much as 53% and triglycerides by nearly 45% (28).

While controlled human studies have reported less dramatic results, there have still been some impressive improvements in these markers (3456).

In a 60-day study of chronically stressed adults, the group taking the highest dosage of ashwagandha experienced a 17% decrease in LDL cholesterol and an 11% decrease in triglycerides, on average (3).

BOTTOM LINE:Ashwagandha may help reduce the risk of heart disease by decreasing cholesterol and triglyceride levels.

11. It May Improve Brain Function, Including Memory

Test-tube and animal studies suggest that ashwagandha may reduce memory and brain function problems caused by injury or disease (29303132).

Researchers have shown that it promotes antioxidant activity that protects nerve cells from harmful free radicals.

In one study, epileptic rats treated with ashwagandha had nearly a complete reversal of spatial memory impairment. This was likely caused by a reduction in oxidative stress (32).

Although ashwagandha has traditionally been used to boost memory in Ayurvedic practice, at this point there is only a small amount of human research in this area.

In a controlled study, researchers who gave healthy men 500 mg of the herb daily reported significant improvements in their reaction time and task performance, compared to men who received a placebo (33).

BOTTOM LINE:Ashwagandha supplements may improve brain function, memory, reaction times and the ability to perform tasks.

12. Ashwagandha is Safe for Most People and Widely Available

Ashwagandha appears to be a safe supplement for most people.

However, certain individuals should not take it, including pregnant and breastfeeding women.

People with autoimmune diseases should also avoid ashwagandha unless authorized by a doctor.

This includes people with conditions like rheumatoid arthritis, lupus, Hashimoto's thyroiditis and type 1 diabetes.

Additionally, those on medication for thyroid disease should be careful when taking ashwagandha, as it may potentially increase thyroid hormone levels in some people.

It may also decrease blood sugar and blood pressure levels, so medication dosages may need to be adjusted if you take it.

Ashwagandha dosages in studies typically ranged from 125–1,250 mg daily. In studies where different dosages were taken, the higher dosage usually produced the most dramatic improvements.

If you want to supplement with ashwagandha, look for root extract or powder in 450–500 mg capsules and take it once or twice per day.

It is offered by several supplement manufacturers and available in health food stores, vitamin shops and from various online retailers.

BOTTOM LINE:Although ashwagandha is safe for most people, certain individuals shouldn't use it unless authorized by their doctor. The recommended dosage is 450–500 mg once or twice per day.

Take Home Message

Ashwagandha is a traditional medicinal herb with multiple health benefits.

It can reduce anxiety and stress, help fight depression, boost fertility and testosterone in men, and may even boost brain function.

Supplementing with ashwagandha may be an easy and effective way to improve your health and quality of life.


New Thread: Nifty forms ‘Doji’ candle ahead of Muhurat Trading

From : Yatheendradas C.k. at 07:00 PM - Oct 18, 2017 ( )

Oct 18, 2017 05:51 PM IST | Source: Moneycontrol.com

Technical View: Nifty forms ‘Doji’ candle ahead of Muhurat Trading

On the options front, maximum Put OI was seen at 10,000 followed by 9,900 while maximum Call OI is at 10,200 followed by 10,300 strikes.

By Kshitij Anand

The Nifty5o which opened with a gap on the lower failed to hold on to gains and slipped in red after rallying for four consecutive days in a row on Wednesday. It made a ‘Doji’ type of pattern for the second consecutive day in a row.

India market will open for an hour from 06:30 pm to 07:30 pm on Thursday on account of Muhurat Trading. The market will remain shut on Friday on account of Diwali Balipratipada.

Doji candlestick pattern signifies indecisiveness between bulls and bears. It could also be a sign that the current trend might be losing strength and investors should pocket some gains ahead of the long weekend.

The Nifty opened at 10,209 and slipped marginally to 10,175. It rose to a record high of 10,236.45 before closing the day at 10,210.85.


“The Nifty50 registered a Doji formation after a gap down opening as it recouped all intraday losses before signing off the truncated week. Last three trading sessions were full of caution with indecisive formations like consecutive Dojis for two days in a row and one Hanging Man kind of formation on last Monday are only pointing towards impending weakness,” Mazhar Mohammad, Chief Strategist – Technical Research & Trading Advisory, Chartviewindia.in told Moneycontrol.

“Moreover, our twin momentum oscillators generated sell signal which has higher accuracy in catching short-term turning points. Added to this Bank Nifty clearly appears to have resumed its downswing with a gap down opening,” he said.

Mohammad further added that the probability of extending correction in next few regular sessions can’t be ruled out. “We advise traders not buy the dip in a hurry but to go long only on further strength above 10,251 levels,” he said.

The Nifty future closed flat to negative with the loss of 0.07 percent at 10,247. India VIX declined by 0.60 percent at 11.54. Bank Nifty has been underperforming the Nifty index as it fell down sharply and closed with the loss of 1.35 percent compared to the Nifty loss of 0.23 percent.

The index has support at 24,250 and then towards 24,000 while on the upside hurdles are seen at 24,500 and then towards 24850. The Bank Nifty has to perform if the index has to continue its up move, suggest experts.

On the options front, maximum Put OI was seen at 10,000 followed by 9,900 while maximum Call OI is at 10,200 followed by 10,300 strikes.

“We have seen Put writing at 10,000 followed by 10,200 strikes while Call unwinding was seen at 10,100 strikes. Fresh Put writing with Call unwinding is shifting its support to higher zones but intact Call writing at 10,300 is restricting its upside momentum,” Chandan Taparia, Derivatives and Technical Analyst at Motilal Oswal Securities told Moneycontrol.

“Rising Put Call Ratio with lower volatility suggests an overall bullish bias of the market. However, Bank Nifty has been underperforming and 750 points from its highs while Nifty is up by around 50 points from its previous high of 10,178,” he said.

New Thread: Top 10 stocks to buy in Muhurat Trading

From : Yatheendradas C.k. at 06:57 PM - Oct 18, 2017 ( )

Oct 18, 2017 05:24 PM IST | Moneycontrol.com

Top 10 stocks to buy in Muhurat Trading which could give up to 48% upside in Samvat 2074

Here is a list of top 10 stocks to buy this Muhurat Trading day for a potential upside of up to 48% in Samvat 2074.

By  Kshitij Anand

Samvat 2073 turned out to be a good investment year for equity investors and Samvat 2074 is unlikely to disappoint investors.

Analysts advise investors to remain stock specific rather than focussing just on the S&P BSE Sensex or the Nifty. High valuations and mixed macro data could bring short-term pain otherwise Indian markets are in a structured bull market.

Here is a list of top 10 stocks to buy this Muhurat Trading day for a potential upside of up to 48% in Samvat 2074:

Analyst: Achin Goel, Head of Wealth Management and Financial Planning, Bonanza Portfolio Ltd


National Peroxide: BUY| Target Rs2965| Return 48%

National Peroxide, controlled by the Wadia Group, is the largest domestic producer of hydrogen peroxide, with a current capacity of 95,000 MTPA and has a domestic market share of 45 percent.

National Peroxide is benefitted from Anti-Dumping duty as it has been levied on Hydrogen Peroxide for a period of 5 years on imports from six countries i.e. Bangladesh, Taiwan, South Korea, Indonesia, Pakistan, and Thailand. In India imports of hydrogen peroxide contribute nearly 20 percent of demand.

Its market leadership position, new capacity expansion, the strong domestic demand of Hydrogen Peroxide makes us buoyant about NPL growth story. The stock trades at 23.3x its FY19E earnings.

Sintex Plastics Technology: BUY| Target Rs135| Return 48%

Sintex Plastics Technology Limited (SPTL), is a globally respected conglomerate with interests across building materials and custom moulding. The company enjoys global presence with 36 manufacturing facilities spread across India, Europe, North Africa & USA.

SPTL is currently trading at 12.4x FY17 EPS of Rs. 7.6 which is attractive considering other plastic companies like Nilkamal and Supreme Industries which are trading at a PE of 20 and 33 respectively.

The brokerage firm recommends a BUY call on SPTL at a PE 12x of 2019 EPS with a target price of Rs.135, upside of 48%.

V2 Retail: BUY| Target Rs 604| Return 15%

V2 Retail is engaged in the business of retail sales of garments, textiles, accessories and consumer durables products in India. V2 Retail has shown strong growth trajectory over FY15- FY17 with sales/EBITDA/PAT growth of 28%/19%/96%, respectively.

Operating margin improved from 0.7% in FY13 to 8.3% in FY17. The company currently operates in 13 states with 44 stores having a total retail area in excess of 5.25 lacs sq. ft.

On a net level, it added 15 stores in FY17 and going forward the management has given guidance that the company intends to add 25 stores per year with a revenue growth of 40% CAGR for the next 3 years.

Bonanza maintains FY 18/19 EPS to Rs.9.1/Rs.15.1 given the strong revenue growth visibility with a target multiple to 40x on account of improved growth outlook.

Capital First: BUY| Target Rs966| Return 27%

Capital First Ltd (CPL), is a leading Indian NBFC providing debt financing to MSMEs and consumers in India. CPL has financed over 4.5 million customers in more than 225 locations across India.

We believe with the good asset quality, market share gain in 2-wheeler and its ability to deliver strong earnings would benefit CPL to deliver strong sustainable performance and capitalize on emerging opportunities.

At CMP the stock trades at 2.87x its FY18E ABV and 2.51x its FY19E ABV. We value CPL at FY19E P/ABV multiple of 3.2x to arrive at target price of Rs 966, upside of 28 percent.

Pondy Oxides: BUY| Target Rs850| Return 38%

Pondy Oxides & Chemicals Limited (POCL) produces the highest quality lead and lead alloys and PVC additives which are supplied to battery manufacturers, chemical manufacturers and PVC extruded and moulded products

During FY 13-17, company revenue has grown at a CAGR of 21 percent and PAT has grown at a CAGR of 71 percent. We are expecting company’s revenue to grow at 18% CAGR for next 3 years as Lead demand in India will be strong.

POCL is trading at 11.7x FY17 EPS of Rs50.1 and 7.3x FY19E EPS of Rs80.6. The brokerage firm recommends a BUY call on POCL at a PE 10.5x of 2019 EPS with a target price of Rs. 850, upside of 42 percent.

Brokerage Firm: Axis Direct

APL Apollo Tubes: BUY| Target Rs2195| Return 15%

APL Apollo trades at an attractive 14.5x its FY19E despite reporting robust volume growth of over 42 percent CAGR over the last 10 years.

Further, having reported strong ROE of over 23% compared to its peers, it is still a better place to capture the fast-growing opportunities.

The brokerage firm believes that APL Apollo would grow at a faster pace of 21%/26/36% of Revenue/EBITDA/PAT CAGR than the industry over FY17-FY19E.

Dilip Buildcon: BUY| Target Rs867| Return 9%

Dilip Buildcon is one of the largest and fastest growing private sector road focussed Engineering Procurement Construction (EPC) contractors in the country.

The brokerage firm maintains their FY18/19 EPS to Rs42/51 given the strong revenue growth visibility with a target multiple to 17x to account for improved growth outlook and RoCE (return on capital employed) of the business.

With the monetisation of the BOT assets, DBL has delivered on its strategy of being focused EPC player in the infrastructure space.

Jagran Prakashan: BUY| Target Rs205| Return 20%

Jagaran Prakashan Ltd is a media company with businesses across printing and publication of newspapers and magazines, FM Radio, Digital, outdoor advertising, promotional marketing and event management.

Higher ad-spends are witnessed at a time of central and state elections which have aided revenue growth due to increase in campaign-related activities. The upcoming state elections in 2018, state and general elections in 2019 present significant opportunities.

The brokerage firm fee that Jagran is well placed to benefit from this opportunity given its presence across media segments.

Maruti Suzuki: BUY| Target Rs9298| Return 28%

Maruti Suzuki will be able to maintain its leadership position through new models pipeline, strong distribution network, and 2-year revenue visibility which makes the brokerage firm buoyant about the automaker's growth story. The stock is valued at 27x PE its FY19E earnings.

Capex guidance for FY18 stands at Rs4500 crore which will be towards new products, R&D, annual maintenance and building market infrastructure. The company has set up a dedicated vertical for acquiring land for dealerships in existing/new locations.

Minda Corporation: BUY| Target Rs183| Return 26%

Minda Corporation is a diversified auto-ancillary with product portfolio encompassing from safety Security and Restraint Systems. It caters to all key segments of PV, CV, 2/3W, tractors etc.

Minda Corp derived 39 percent of its revenues from Safety and Security Systems, 47% from Driver Information and Telematics Systems, 14% from interior systems in FY17. In terms of end market, 31% of the revenues were contributed by 2/3 wheeler, 36% from PV’s, 23% from CVs and 10% from the aftermarket.

DisclaimerThe views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.


New Thread: IPO boom of 2017: Promoters make moolah, not companies.

From : Yatheendradas C.k. at 03:53 PM - Oct 18, 2017 ( )

IPO boom of 2017: Promoters make moolah, not companies. Here’s who booked profits

2017 has been the year of IPOs. This year, as many as about 30 companies have raised over Rs 50,000 crore so far. However, this year, the number of IPOs where promoters were selling their shares, or part exiting their shareholding in the companies, was high as well.

By: FE Online | Published: October 18, 2017 2:29 PM

2017 has been the year of IPOs. This year, as many as about 30 companies have raised over Rs 50,000 crore so far. Five mega insurance IPOs including SBI Life and ICICI Lombard — are poised to raise nearly Rs 40,000 crore by the end of the year, and even IPO of smaller companies such as Prataap Snacks and DMart(Avenue Supermarts) witnessed unprecedented oversubscriptions.


However, this year, the number of IPOs where promoters were selling their shares, or part exiting their shareholding in the companies, was high as well. When shareholders sell their shares through IPO, it means the proceeds made from the IPO will go directly to promoters, not companies.

An initial public offering (IPO) is the first time that the stock of a private company is offered to the public. The company offers fresh shares for IPO, while company’s promoters can also sell their shares through offer for sale. In offer for sale, money received through IPO will not go to the company, but will go to promoters who are selling their shares.

Here are few of the prominent IPOs of 2017, in which the promoters sold a part of their stakes

SBI Life: SBI Life Insurance’s Rs 8,400 crore IPO was oversubscribed 2.6 times. However, it was a pure offer for sale with SBI selling 8% stake and BNP Paribas selling 4%. The entire proceeding of Rs 8,400 crore went to its parent company SBI and BNP Paribas.

ICICI Lombard: ICICI General Insurance Co Ltd’s Rs 5,700 crore IPO was oversubscribed 1.97 times. It was also an entirely offer for sale IPO with its parent company ICICI Bank and Fairfax diluting 19% shares for Rs 5,700 crore.

Godrej AgrovetGodrej Agrovet Ltd’s Rs 1,157 crore IPO had a total issue of 1.8 crore shares, of which the parent company Godrej Industries sold shares worth Rs 300 crore.

Reliance Nippon: Reliance Nippon Life Asset Management will open its IPO on October 25. The company is aiming to raise around Rs 1,542 crore. However, with an offer for sale comprising 3.66 crore shares, Rs 925.2 crore of the total Rs 1,542 crore will go the promoters Nippon Life and Reliance Capital.

AU Small Finance BankAU Small Finance Bank’s Rs 1,912 crore public issue was also oversubscribed by 53 times. Of the total issue of 5.35 crore shares, 3.77 crore shares were offered by the promoters, through which their proceed was Rs 1,349 crore.

BSE Ltd: The IPO of BSE Ltd, owner of the Bombay Stock Exchange was also purely an offer for sale. BSE’s existing shareholders sold a total of 1.54 crore shares for a total of Rs 1,241 crore, with no fresh equity going to the company.

Security and Intelligence ServicesSecurity and Intelligence Services India Ltd’s Rs 780 crore IPO was oversubscribed 6.96 times. While the total issue was 5.4 lakh shares, promoters sold 5.12 lakh shares, making Rs 751 core.

Eris Lifesciences LtdEris Lifesciences Ltd’s Rs 1,741 crore IPO was oversubscribed 3.28 times. It was also entirely a sale of existing shares, with ChrysCapital and some of the founding shareholders selling 1.54 crore shares and netting all the proceeds.

New Thread: Thoughts for the Day August 18th, 2017

From : Yatheendradas C.k. at 06:05 AM - Oct 18, 2017 ( )

18th October, 2017  

Image result for quotes for the day

New Thread: Nifty forms ‘Doji’ kind of pattern on charts

From : Yatheendradas C.k. at 07:50 PM - Oct 17, 2017 ( )

Oct 17, 2017 05:48 PM IST | Source: Moneycontrol.com

Technical View: Nifty forms ‘Doji’ kind of pattern on charts; book partial profits

Fresh Put writing was seen at 10,200, 10,250 and 10,300 strikes while Call writing was seen at 10,200 to 10,400 strikes.

By Kshitij Anand

The Nifty50 rose to a record high on Tuesday but witnessed some profit taking towards the close of the session. The index made an indecisive candle in the form Doji which suggests that neither bulls nor bears were able to gain control over the market.

Doji candlestick pattern signifies indecisiveness between bulls and bears. It could also be a sign that the current trend might be losing strength and investors should pocket some gains ahead of the long weekend.

Indian market will remain shut on Thursday and Friday on account of Diwali where it will open for an hour only and Diwali Balipratipada on Friday.

The Nifty opened at 10,227 and slipped marginally to 10,212. It rose to a record high of 10,215.85 before closing the day at yet another closing high of 10,234.45.


“It was a day of consolidation on the bourses as Nifty50 moved in a narrow range of 38 points before signing off the day with an indecisive formation which resembles Doji. This kind of pause is pretty much warranted as markets reached overbought zones after a sharp run-up witnessed in last 4 trading sessions,” Mazhar Mohammad, Chief Strategist – Technical Research & Trading Advisory, Chartviewindia.in told Moneycontrol.

“Markets may undergo a correction in short-term if they were to close below 10,200 levels in next trading session. Hence, it looks inevitable for the Nifty50 to sustain above 10,250 levels in immediate trading session to avoid any short-term damage,” he said.

Mohammad advises short-term traders to book part profit, ahead of the long weekend, in next trading session as indices trade around 10,250.

India VIX moved up by 2.65 percent at 11.61. Overall, lower volatility with historical high Put Call Ratio suggests that Put writers are holding the tight grip on the market thus downside seems to be limited.

On the options front, maximum Put OI was seen at 10000 followed by 9900 strikes while maximum Call OI was seen at 10200 followed by 10300 strikes.

Fresh Put writing was seen at 10,200, 10,250 and 10,300 strikes while Call writing was seen at 10,200 to 10,400 strikes.

“Option data suggests that supports are shifting higher but Call writing at 10,300 could restrict momentum or pace of buying interest,” Chandan Taparia, Derivatives and Technical Analyst at Motilal Oswal Securities told Moneycontrol.

“Nifty index made a new lifetime high of 10,251.85; however, momentum was missing as it formed a small candle and traded in a range of around 38 points for the entire day,” he said.

Taparia further added that the index has to hold above 10,250 zone to extend its move towards 10,300 then 10,400 while supports are seen at 10,170 then 10,150.


New Thread: Stocks of Reliance Industries, Axis Bank, Bajaj Auto et

From : Yatheendradas C.k. at 09:16 AM - Oct 17, 2017 ( )

Stocks of Reliance Industries, Axis Bank, Bajaj Auto, Wipro, ACC, ICICI Lombard will be in focus today

Sensex and Nifty are likely to open higher on Tuesday following the earnings optimism and the record closing of Wall Street shares on Monday.

By: FE Online | Published: October 17, 2017 8:47 AM

Sensex and Nifty are likely to open higher on Tuesday following the earnings optimism and the record closing of Wall Street shares on Monday. The early indicator of NSE Nifty — SGX Nifty Futures — was trading little changes, down 0.21% at 10,259.5 points on the Singapore Stock Exchange.


These shares will be in watch today ahead of their Q2 results

Axis Bank, Bajaj Auto, Wipro, ACC, AB Money, Atul Ltd, Bajaj Holdings, Blue Dart, Crisil, ICICI Lombard, Nucleus Software, Prakash Industries, RS Software, Som Distilleries, TataSponge.

Stocks in focus today

Reliance Industries: Reliance Industries and its partner BP Plc of UK today submitted a revised investment plan for bringing to production the satellite gas discoveries in the flagging KG-D6 block. RIL and BP plan to develop four deepsea satellite gas finds, named D-2, 6, 19 and 22, together with two other nearby finds, D-29 and D30, in the Krishna Godavari basin block, PTI reported citing unidentified sources.

Bajaj Finance: In spite of some impact arising from the GST rollout disruptions, leading non-banking finance player Bajaj Finance reported a 37 per cent jump in net profit at Rs 557 crore for the quarter to September, as overall advances grew at a healthy pace.

Colgate-Palmolive (India): FMCG firm Colgate-Palmolive (India) Ltd reported a 2.06 per cent decline in its net profit at Rs 177.57 crore for the second quarter ended September 30.

Persistent Systems: Mid-sized software services player Persistent Systems reported a 12.4 per cent growth in September quarter net at Rs 82.36 crore on volume growth and margin expansion on efficiencies.

Oberoi Realty: Oberoi Realty reported a 25 per cent surge in its consolidated net profit to Rs 104.32 crore for the second quarter ended September 30.

Sterlite technology: Sterlite technology posted a 40 per cent surge in consolidated net profit to Rs 71.23 crore in the second quarter ended September 30, driven by demand for optical fibre cable for high speed data networks.

DHFL: Housing financier DHFL reported a 26.1 per cent rise in net profit to Rs 293.30 crore for the quarter ended in September this year compared to Rs 232.62 crore in the same period of last year.

DCB Bank: Small sized private sector lender DCB Bank reported 21 per cent rise in its September quarter net at Rs 59 crore on core income growth.

MCX: Largest commodity bourse MCX would unveil the country’s first commodity options trading with gold on the auspicious occasion of Dhanteras. The gold options will be launched today on Dhanteras in presence of Finance Minister Arun Jaitley in New Delhi, PTI reported.

Indian Rupee on Monday: The rupee ended at more than three-week high of 64.74 a dollar, surging by 19 paise helped by extremely bullish macro indicators.

Indian markets on Monday

Sensex and Nifty closed at fresh record highs on Monday with just two days left for the Muhurat trading on Diwali. BSE Sensex gained 201 points to close at 32,633.64 points while NSE Nifty added 63 points to finish at 10,230.85 points. During the day, the broader Nifty 50 jumped 75.5 points to hit the all-time high of 10,242.95 points while the benchmark Sensex advanced 254.63 points to mark the new lifetime of 32,687.32 points. Shares of Bharti Airtel, Vedanta, and Bharti Infratel were the biggest gainers on NSE Nifty. The value buying in the blue-chip shares such as Airtel, Hindustan Unilever, and Tata Motors pushed the indices to mark lifetime highs.

US markets on Monday

All three major US stock index rose to record closing highs on Monday, with the Dow Jones Industrial Average less than 50 points below 23,000, ahead of a long list of earnings this week and as financial shares recovered from last week’s losses, Reuters reported. The Dow Jones Industrial Average rose 85.24 points, or 0.37 percent, to close at 22,956.96, the S&P 500 gained 4.47 points, or 0.18 percent, to 2,557.64 and the Nasdaq Composite added 18.20 points, or 0.28 percent, to 6,624.01.

New Thread: Motion Induced Blindness

From : Yatheendradas C.k. at 06:09 AM - Oct 17, 2017 ( )

Please read this carefully and practice it too.. It is true that speed can induce blindness and I have experienced it, especially on long drives on highways. I am sure you have ...too.



Motion Induced Blindness

New Thread: Sugar, not fat, exposed as deadly villain in obesity

From : Yatheendradas C.k. at 06:03 AM - Oct 17, 2017 ( )

Sugar, not fat, exposed as deadly villain in obesity epidemic

It's addictive and toxic, like a drug, and we need to wean ourselves off it, says US doctor

sugar obesity
Dr Robert Lustig's book Fat Chance: The Bitter Truth About Sugar has caused a backlash from the food industry, which, he says, wants to 'paint me as this zealot'. Photograph: Alamy

Sugar – given to children by adults, lacing our breakfast cereals and a major part of our fizzy drinks – is the real villain in the obesity  epidemic, and not fat as people used to think, according to a leading US doctor who is taking on governments and the food industry.

Dr Robert Lustig, who was this month in London and Oxford for a series of talks about his research, likens sugar to controlled drugs. Cocaine and heroin are deadly because they are addictive and toxic – and so is sugar, he says. "We need to wean ourselves off. We need to de-sweeten our lives. We need to make sugar a treat, not a diet staple," he said.

"The food industry has made it into a diet staple because they know when they do you buy more. This is their hook. If some unscrupulous cereal manufacturer went out and laced your breakfast cereal with morphine to get you to buy more, what would you think of that? They do it with sugar instead."

Lustig's book, Fat Chance: The Bitter Truth About Sugar has made waves in America and has now been published in the UK by 4th Estate. As a paediatrician who specialises in treating overweight children in San Francisco, he has spent 16 years studying the effects of sugar on the central nervous system, metabolism and disease. His conclusion is that the rivers of Coca-Cola and Pepsi consumed by young people today have as much to do with obesity as the mountains of burgers.

That does not mean burgers are OK. "The play I'm making is not sugar per se, the play I'm making is insulin," he says. Foodstuffs that raise insulin levels in the body too high are the problem. He blames insulin for 75% to 80% of all obesity. Insulin is the hormone, he says, which causes energy to be stored in fat cells. Sugar energy is the most egregious of those, but there are three other categories: trans fats (which are on the way out), alcohol (which children do not drink) and dietary amino acids.

These amino acids are found in corn-fed American beef. "In grass-fed beef, like in Argentina, there are no problems," he said. "And that's why the Argentinians are doing fine. The Argentinians have a meat-based diet … I love their meat. It is red, it's not marbled, it's a little tougher to cut but it's very tasty. And it's grass-fed. That's what cows are supposed to eat – grass.

"We [in the US] feed them corn and the reason is twofold – one, we don't have enough land and, two, when you feed them corn they fatten up. It usually takes 18 months to get a cow from birth to slaughter. Today it takes six weeks and you get all that marbling in the meat. That's muscle insulin resistance. That animal has the same disease we do, it's just that we slaughter them before they get sick."

But his bigger message is that cheap sugar is endangering lives. It has been added to your diet, "kids have access" to it, and it is there in all sorts of foods that don't need it, he says. When high-fat foods were blamed for making us overweight, manufacturers tumbled over each other to produce low-fat products. But to make them palatable, they added sugar, causing much greater problems.

Cutting calories is not the answer because "a calorie is not a calorie". The effect of a calorie in sugar is different from the effect of a calorie in lean grass-fed beef. And added sugar is often disguised in food labelling under carbohydrates and myriad different names, from glucose to diastatic malt and dextrose. Fructose – contained in many different types of sugar – is the biggest problem, and high-fructose corn syrup, used extensively by food manufacturers in the US, is the main source of it.

Lustig says he has been under attack from the food industry, but claims they have not managed to fault the science. "The food industry wants to misinterpret because they want to discredit me. They want to paint me as this zealot. They want to paint me as somebody who doesn't have the science. But we do," he says.

Evidence of dietary effects on the body is very hard to collect. People habitually lie in food diaries or forget what they ate. Randomised controlled trials are impossible because everyone reverts to a more normal eating pattern after a couple of months. But his sugar argument is more than hypothesis, he says, citing a recent study in the open journal Plos One, of which he was one of the authors. It found that in countries where people had greater access to sugar, there were higher levels of diabetes. Rates of diabetes went up by about 1.1% for every 150 kcal of sugar available for each person each day – about the amount in a can of Coke. Critics argued sugar availability was not the same as sugar consumed, but Lustig and his colleagues say it is the closest approximation they could get.

That study was aimed at the World Health Organisation although he believes it is a conflicted organisation.

But so is the US government, he says. "Government has tied its wagon to the food industry because, at least in America, 6% of our exports are food. That includes the legislative and executive branches. So the White House is in bed with the food industry and Congress apologises for the food industry."

Michelle Obama appeared to be onside when she launched her Let's Move initiative in February 2010 with a speech to the Grocery Manufacturers Association of America. "She took it straight to them and said, 'You're the problem. You're the solution.' She hasn't said it since. Now it's all about exercise.

"Far be it from me to bad-mouth somebody who wants to do the right thing. But I'm telling you right now she's been muzzled. No question of it." In his book he tells of a private conversation with the White House chef, who he claims told him the administration agreed with him but did not want a fight with the food industry.

Some areas of the food industry have appeared to be willing to change. PepsiCo's chief executive officer, Indra Nooyi, who is from India which has a serious diabetes epidemic, has been trying to steer the company towards healthier products. But it has lost money and she is said to be having problems with the board. "So here's a woman who is trying to do the right thing and can't," he says.

Court action may be the way to go, he says, suggesting challenging the safety of fructose added to food, and food labelling that fails to tell you what has been added and what has been taken out. Fruit juice is not so healthy, he says, because all the fibre that allows the natural sugars to be processed without being stored as fat has been removed. Eat the fruit, he says, don't drink the juice. Lustig is taking a master's at the University of California Hastings college of law, in order to be a better expert witness and strategist.

It is not a case of eradicating sugar from the diet, just getting it down to levels that are not toxic, he says. The American Heart Association in 2009 published a statement, of which Lustig was a co-author, saying Americans consumed 22 teaspoons of it a day. That needs to come down to six for women and nine for men.

"That's a reduction by two thirds to three quarters. Is that zero? No. But that's a big reduction. That gets us below our toxic threshold. Our livers have a capacity to metabolise some fructose, they just can't metabolise the glut that we've been exposed to by the food industry. And so the goal is to get sugar out of foods that don't need it, like salad dressing, like bread, like barbecue sauce." There is a simple way to do it. "Eat real food."

Does he keep off the sweet stuff himself? "As much as I can. I don't go out of my way. It finds me but I don't find it. Caffeine on the other hand …"

Lustig's food advice 

• Oranges. Eat the fruit, don't drink the juice. Fruit juice in cartons has had all the fibre squeezed out of it, making its sugars more dangerous.


• Beef. Beef from grass-fed cattle as in Argentina is fine, but not from corn-fed cattle as in the US.


• Coca-Cola, Pepsi and other sweetened beverages. These deliver sugar but with no nutritional added value. Water and milk are the best drinks, especially for children.


• Bread. Watch out for added sugar in foods where you would not expect it.


• Alcohol. Just like sugar, it pushes up the body's insulin levels, which tells the liver to store energy in fat cells. Alcohol is a recognised cause of fatty liver disease.


• Home-baked cookies and cakes. If you must eat them, bake them yourself with one third less sugar than the recipe says. Lustig says they even taste better that way.


From the Web

New Thread: Thoughts for the Day October 17th, 2017

From : Yatheendradas C.k. at 05:57 AM - Oct 17, 2017 ( )

17th October, 2017  

Greatness is a road leading towards the unknown. - Charles de Gaulle

Messages Posted by Yatheendradas C.k.
Home Remedies for KIDNEY DETOXIFICATION 1General Discussion 20 Oct , 2017
Diagnosing cancer 1General Discussion 20 Oct , 2017
Wealth creating opportunity! Metal sector to outperform1Metal Sector 20 Oct , 2017
Thoughts for the Day October 20th, 20171General Discussion 20 Oct , 2017
30 years since Dow’s Black Monday: The lethal cocktail 1General Discussion 19 Oct , 2017
FINANCIAL NEWS IN A NUT SHELL1General Discussion 19 Oct , 2017
Dow touches 23,000 for the first time, closes at record1Market Outlook 19 Oct , 2017
Eye Health: 4 Natural Ways To Maintain Good Vision 1General Discussion 19 Oct , 2017
BSNL Diwali offer: Save your computer from viruses etc1General Discussion 19 Oct , 2017
Thoughts for the Day August 19th, 20171General Discussion 19 Oct , 2017
1 to 10 of 8797<< Previous Next >>